跳转至内容
Merck
CN

PHR1052

Supelco

甲硝唑

Pharmaceutical Secondary Standard; Certified Reference Material

别名:

2-甲基-5-硝基咪唑-1-乙醇

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C6H9N3O3
CAS号:
分子量:
171.15
Beilstein:
611683
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

certified reference material
pharmaceutical secondary standard

质量水平

Agency

traceable to BP 603
traceable to Ph. Eur. M1850000
traceable to USP 1442009

API类

metronidazole

CofA

current certificate can be downloaded

技术

HPLC: suitable
gas chromatography (GC): suitable

mp

159-161 °C (lit.)

应用

pharmaceutical (small molecule)

格式

neat

储存温度

2-30°C

SMILES字符串

CC1=NC=C([N+]([O-])=O)N1CCO

InChI

1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3

InChI key

VAOCPAMSLUNLGC-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Metronidazole is a 5-nitroimidazole derivative that is an effective agent against the diseases caused by anaerobic protozoa and bacteria. It is known to exert radio-sensitizing impact on hypoxic tumour cells.

应用

Metronidazole may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations by chromatography techniques.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

分析说明

These secondary standards offer multi-traceability to the USP, EP (PhEur) and BP primary standards, where they are available.

其他说明

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

附注

To see an example of a Certificate of Analysis for this material enter LRAC0264 in the slot below. This is an example certificate only and may not be the lot that you receive.

推荐产品

Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.

象形图

Health hazard

警示用语:

Danger

危险声明

危险分类

Carc. 1B - Muta. 1B - STOT RE 2

WGK

WGK 3


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Simultaneous determination of metronidazole and miconazole in pharmaceutical dosage forms by RP-HPLC
Akay C, et al.
Il Farmaco (Societa Chimica Italiana : 1989), 57(11), 953-957 (2002)
Electrochemical reduction of metronidazole at activated glassy carbon electrode and its determination in pharmaceutical dosage forms
Ozkan SA, et al.
Journal of Pharmaceutical and Biomedical Analysis, 17(2), 299-305 (1998)
Simultaneous determination of miconazole nitrate and metronidazole in different pharmaceutical dosage forms by gas chromatography and flame ionization detector (GC-FID).
Ashour S and Kattan N
International Journal of Biomedical Science : IJBS, 6(1), 13-13 (2010)
T H I Brummer et al.
BJOG : an international journal of obstetrics and gynaecology, 120(10), 1269-1276 (2013-06-22)
To evaluate cefuroxime and metronidazole antibiotic prophylaxis. Observational nonrandomised 1-year prospective cohort study. Fifty-three hospitals in Finland. A total of 5279 women undergoing hysterectomy for benign indications, with cefuroxime given to 4301 and metronidazole given to 2855. Excluding other antibiotics
Christina M Surawicz et al.
The American journal of gastroenterology, 108(4), 478-498 (2013-02-27)
Clostridium difficile infection (CDI) is a leading cause of hospital-associated gastrointestinal illness and places a high burden on our health-care system. Patients with CDI typically have extended lengths-of-stay in hospitals, and CDI is a frequent cause of large hospital outbreaks

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门